Dr. Daniel Cameron

Lyme Disease Canada: Bill C-442 Offers Hope for Patients The unanimous passage of Bill C-442 marks a major step forward for Lyme disease patients in Canada. This legislation aims to improve awareness, diagnosis, treatment, and coordination of care for a disease that has long been misunderstood. :contentReference[oaicite:0]{index=0} For many patients, this progress comes after years—sometimes […]

Chronic Fatigue vs Lyme Disease: Debate Highlights Diagnostic Divide The debate over chronic fatigue vs Lyme disease diagnosis remains one of the most contentious issues in medicine. A recent Canadian Senate hearing on Bill C-442 brought these differences into sharp focus. :contentReference[oaicite:0]{index=0} At the center of the discussion: whether patients with persistent symptoms are being

Lyme Disease Canada Debate: Bill C-442 and the Risk of Underestimation The Lyme disease Canada Bill C-442 debate highlights a critical question: is the burden of Lyme disease being underestimated? :contentReference[oaicite:0]{index=0} Although Canadian researchers acknowledge that endemic and at-risk regions for ticks expanded from 1 region in 1997 to 13 regions by 2006, some have

When Patients Know More Than Doctors Guest Blog By Jennifer Bybel Lown, Nurse Practitioner Dr. Daniel Cameron & Associates Lyme disease patient advocacy has become an essential part of care, especially when the illness is misunderstood or misdiagnosed. In many cases, patients and their families become the most informed voices in the diagnostic process. Patients

Borrelia miyamotoi FDA Test: Why the Diagnostic Gap Matters The FDA Testing Gap for Emerging Tick-Borne Diseases There is currently no FDA-approved test for Borrelia miyamotoi. This gap highlights a larger problem in diagnostic medicine: emerging tick-borne infections are being identified faster than regulatory pathways can support testing. :contentReference[oaicite:0]{index=0} If testing were limited only to

Lyme Disease Treatment: Why One Size Does Not Fit All Lyme disease individualized treatment is essential because patients vary widely in symptoms, response to therapy, and clinical course. A uniform approach may not address the complexity of this infection. A review of the International Lyme and Associated Diseases Society (ILADS) 2014 evidence-based guidelines highlights this

Fibromyalgia vs Lyme Disease: Could Infection Be Missed? Fibromyalgia vs Lyme disease is a critical diagnostic challenge, as both conditions share overlapping symptoms that can lead to missed or delayed diagnosis. After decades of treating Lyme disease, I have seen patients initially diagnosed with fibromyalgia improve when underlying infection is addressed. This overlap raises an

The task force by Executive Order must submit an action plan by February 15, 2015, outlining specific steps on how to implement a national strategy to combat antibiotic resistance and accelerate research and development on new antibiotics by 2020. The task force will be led by the secretaries of Health and Human Services, the Department

Antibiotic Resistance Policy: Impact on Lyme Disease Treatment Efforts to combat antibiotic resistance are essential—but they may have unintended consequences for patients with Lyme disease. The federal task force established by Executive Order was charged with developing a national strategy to address antibiotic resistance and accelerate the development of new treatments. The task force includes